Intratumoral CAN2109 in Subjects With Solid Tumors
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: CAN2109.
- Who it may be relevant to
- Registry conditions: Solid Tumor, Lymphoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN2109 in Subjects With Unresectable or Metastatic Advanced Solid Tumors.
Overview
A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.
Detailed description
The scope of the study is to evaluate the safety of CAN2109 in humans, explore its safety, efficacy and collect data on the pharmacokinetics, as well as on the pharmacodynamic effect of the drug on the immune system locally and systemically, and on tumor markers.
Interventions
- Drug CAN2109
CAN2109 IT injection (once every 3 weeks)
Primary outcome measures
- Safety [Time frame: 12 months]
- Recommended Phase 2 Dose (RP2D) [Time frame: 12 months]
- tolerability [Time frame: 12 months]
Secondary outcome measures (2)
- To determine the efficacy of CAN2109 [Time frame: 12 months]
- To evaluate the pharmacodynamics of CAN2109 [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Able and willing to provide written informed consent and willing to comply with the study's requirements.
- Male or female age ≥ 18 years at screening.
- Metastatic or locally advanced solid tumor that has progressed on, is refractory to, or for which there is no efficacious standard of care therapy. Preferred tumor types include the following:
a. Carcinoma of skin, melanoma, Merkel cell carcinoma (MCC), breast cancer, head and neck squamous cell carcinoma (HNSCC), sarcoma, cervical carcinoma, and colorectal cancer
- Performance status of 0-1 on the ECOG Performance Scale.
Exclusion criteria
- Unresolved toxicities from prior therapy, defined as having not resolved to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (v5.0) Grade 0 or 1, with exception of endocrinopathies from prior therapy, alopecia, and vitiligo.
- Treatment with systemic corticosteroids at doses exceeding 10 mg/day prednisone or equivalent.
- Has an active infection requiring systemic therapy.
- Unstable/inadequate cardiac function defined as follows:
- New York Heart Association Class 3 or 4 congestive heart failure
- uncontrolled hypertension
- acute coronary syndrome within 6 months
- clinical important cardiac arrhythmia
- mean corrected QT (QTc) interval corrected for heart rate > 480 ms.
- A history of interstitial lung disease.
- A history of coagulopathy resulting in uncontrolled bleeding or other bleeding disorders.
- Participated in a clinical study of an investigational agent within 30 days of screening.
- Has known psychiatric, substance abuse, or other disorders that would interfere with cooperation with the requirements of the study in the opinion of the investigator.
- Is pregnant or breastfeeding.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Sun Yat-Sen University Sun Yat-Sen Memorial Hospital — Guangzhou
Identifiers
NCT: NCT06332430 · CW-202